<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="9" ids="27656">CPT</z:chebi>-11 is hydrolyzed to its active metabolite SN-38, which is mainly eliminated through conjugation by hepatic <z:chebi fb="0" ids="17659">uridine diphosphate</z:chebi> glucuronosyl transferases (UGTs) to the <z:chebi fb="0" ids="24302">glucuronide</z:chebi> (SN-38G) derivative </plain></SENT>
<SENT sid="1" pm="."><plain>Preclinical studies showed that UGT*1.1 is the isozyme responsible for SN-38 glucuronidation </plain></SENT>
<SENT sid="2" pm="."><plain>Patients with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> have deficient UGT*1.1 activity, therefore may have an increased risk for related <z:chebi fb="9" ids="27656">CPT</z:chebi>-11 toxicity </plain></SENT>
<SENT sid="3" pm="."><plain>PATIENTS AND METHODS: Two patients with metastatic <z:hpo ids='HP_0003003'>colon cancer</z:hpo> and <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> were treated with <z:chebi fb="9" ids="27656">CPT</z:chebi>-11 based chemotherapy </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="9" ids="27656">CPT</z:chebi>-11, SN-38 and SN-38G pharmacokinetics parameters were obtained </plain></SENT>
<SENT sid="5" pm="."><plain>Serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> was analysed by alkaline methanolysis and HPLC </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Both patients presented grade 4 <z:hpo ids='HP_0001875'>neutropenia</z:hpo> and/or <z:hpo ids='HP_0002014'>diarrhea</z:hpo> (NCI-CTC) in every treatment cycle </plain></SENT>
<SENT sid="7" pm="."><plain>Biliary index (after Gupta et al) values were well above 4000 </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: We present the first clinical evidence linking <z:chebi fb="0" ids="16990">bilirubin</z:chebi> glucuronidation status and <z:chebi fb="9" ids="27656">CPT</z:chebi>-11 related toxicity </plain></SENT>
<SENT sid="9" pm="."><plain>The severe toxicity experienced by the two patients with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> treated with <z:chebi fb="9" ids="27656">CPT</z:chebi>-11 based chemotherapy has a genetic basis </plain></SENT>
<SENT sid="10" pm="."><plain>Individuals with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> have an enhanced risk for <z:chebi fb="9" ids="27656">CPT</z:chebi>-11 toxicity </plain></SENT>
<SENT sid="11" pm="."><plain>Unconjugated serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> could be predictive parameter of <z:chebi fb="9" ids="27656">CPT</z:chebi>-11 toxicity </plain></SENT>
</text></document>